Tomáš Zima
Head of Institute
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Laboratory investigations are important in the clinical management and the study of chronic kidney disease–mineral and bone disorder (CKD-MBD)- including CKD-associated osteoporosis. Parathyroid hormone (PTH) is the major hormone in the regulation of bone and calcium balance but is significantly affected in advanced CKD. Knowledge of PTH concentration is important in the assessment of osteoporosis including CKD-associated osteoporosis; however, measurement of PTH in the laboratory is bedevilled by interferences and inter-method differences compounded by lack of standardisation of commonly used immunoassays. Vitamin D is important for bone health and its deficiency contributes to the development of osteoporosis. Vitamin D metabolism is impaired in advanced CKD, augmenting the effects of its deficiency on bone health. Lack of consensus on optimal serum 25-hydroxyvitamin D (25-(OH)D) concentrations for bone health, including in the various CKD stages, is compounded by lack of analytical specificity of immunoassays. Liquid chromatography tandem mass spectrometry (LC-MS/MS) assays would help overcome these issues. Ionised calcium measurement is recommended for assessment of serum calcium, especially in CKD. Fibroblast growth factor 23 (FGF23) is important in the homeostasis of phosphate that accumulates in CKD, though this marker is not yet utilized in clinical context. Calculated maximal tubular reabsorption of phosphate normalized to glomerular filtration rate (TmP/GFR) may help in assessment of phosphate homeostasis. Bone specific alkaline phosphatase (BALP) and tartrate-resistant acid phosphatase isoform 5b (TRACP5b), the reference markers of bone formation and resorption for CKD-associated osteoporosis, have been shown to reflect bone turnover by histomorphometry in patients with advanced CKD.
Year:
2025
Year:
2025
Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.
Year:
2025
The tau protein is one of the neurocytoskeletal proteins that participate in the pathogenesis of serious neurological diseases, especially Alzheimer's disease. The tau protein is characterized by considerable structural variability, which is reflected in the existence of its numerous proteoforms. This review aims to provide brief information on the structure of tau protein and its proteoforms, which seem promising biomarkers for clinical use. Biological fluids, suitable for laboratory examination in clinical practice, i.e., cerebrospinal fluid and blood (plasma/serum), are discussed. Total tau protein and its phosphorylated forms (mainly the pT181-tau protein, phosphorylated at the threonine residue 181) have already found clinical application in diagnosis of Alzheimer's disease.
Year:
2024
Collaborators (51)
Kathleen Claes
Full professor
Ghent University Hospital
Giuseppe Matullo
-
Lisa Wiesmüller
Professor
Ulm University
Christopher A. Haiman
University of Southern California
Christine Ambrosone
Roswell Park Comprehensive Cancer Center
Eric Hahnen
-
Susan Domchek
Professor, Clinician-Educator
University of Pennsylvania
Sara Lindström
University of Washington
Maria Rossing
Associate Clinical Professor
Copenhagen University Hospital
Marco Montagna
Istituto Oncologico Veneto
Katherine Nathanson
Professor
University of Pennsylvania
Nicoletta Resta
Full Professor Medical Genetics
University of Bari Aldo Moro
Song Yao
Professor
Roswell Park Comprehensive Cancer Center
Maria Piane
Sapienza University of Rome
Sara González
Institut Català d'Oncologia
FEI CHEN
Assistant Professor
University of Southern California
Alexandra Martins
INSERM
Julie R Palmer
Boston University School of Medicine
Alexander E Volk
-
Peter Kraft
Professor
Harvard T.H. Chan School of Public Health
Siddhartha Yadav
Associate Professor of Oncology
Mayo Clinic
Mariarosaria Calvello
European Institute of Oncology
anna coppa
Sapienza University of Rome
Allison DePersia
NorthShore University HealthSystem
Paul James
Head of Adult Genetics
The Royal Melbourne Hospital Royal Park Campus
Florentia Fostira
National Centre for Scientific Research-Demokritos
Paolo Radice
Head of Reserach Unit
Fondazione IRCCS Istituto Nazionale dei Tumori
Maria Elena. Martinez
University of California
Marketa Janatova
Assistanf Professor and researcher
Přírodovědecká Fakulta, Univerzita Karlova
Gareth Evans
The University of Manchester
Giovanni Lombardi
Associate Professor
Akademia Górniczo-Hutnicza im Stanislawa Staszica w Krakowie
Weng Khong Lim
Assistant Professor
Duke-NUS Medical School
Barbara Pasini
Associate Professor of Medical Genetics
Università degli Studi di Torino
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Jeffrey Weitzel
Professor and Director
University of Kansas Cancer Center
Harjit Pal Bhattoa
Associate Professor
University of Debrecen Medical School and Health Science Center
Banu K. Arun
The University of Texas MD Anderson Cancer Center
Paul Auer
Professor
Medical College of Wisconsin
Alvaro Monteiro
Senior Member - Full Professor
H Lee Moffitt Cancer Center and Research Institute
Corinna Ernst
Hannover Medical School
Mathias Haarhaus
Karolinska University Hospital
Kathryn Ruddy
Professor
Mayo Clinic
Hanne Mari Skou Jørgensen
Associate Professor
Aarhus University
Lidia Feliubadaló
Institut Català d'Oncologia
Koichi Matsuda
University of Tokyo
Joanne Ngeow
Head
Nanyang Technological University (NTU)
Zdenek Kleibl
Laboratory of oncogenetics (head)
Charles University, First Faculty of Medicine
Nicholas Boddicker
Research Associate
Mayo Clinic
Amanda Toland
Ohio State University
Laura Cortesi
University of Modena and Reggio Emilia
Make your next move.
Prepare your application
Review drafts before you send them.